Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.

Also called NCT02452736

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 205 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02452736
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02452736. Allocation not applicable; no masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2015-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)
Condition
Ischemic Heart Disease
Condition
Cardiovascular Diseases
Condition
Arteriosclerosis
Intervention (Device)
Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
Lead sponsor
Medtronic Vascular (class: industry)

Record details

Record id
cardio:ct-nct02452736
Content hash
3e4d5f9e679909cc982f940d9b4ecf91b3e79dffb64f766da8daa5232177f858